Conflict of interest declaration: Anthony G Marson

Roles in: Epilepsy Group

1. In the past three years have you accepted the following from an organisation that may gain or lose financially from the publication of reviews by your review group in the Cochrane Database of Systematic Reviews (CDSR)?

a) Reimbursement for attending a conference or symposium (including travel, accommodation and/or hospitality)?
No

b) Fees for speaking?
Yes - Spoke at EISAI funded symposium on evidence based epilepsy management at UK International League Against Epilepsy conference October 2015

c) Fees for organising education?
No

d) Funds for research?
Yes - I lead the National Audit of Seizure Management in Hospitals (NASH) 2013. This was funded by a consortium of pharmaceutical companies: GSK, Eisai, UCB Pharam, VIropharama.

e) Funds for a member of staff?
Yes - Staff are employed to administrate NASH as outlined above.

f) Fees for consulting?
No

g) Royalty payments?
No

2. In the past three years have you or your spouse/partner been employed by an organization that may in any way gain or lose financially from the publication of reviews by your review group in the CDSR?
No

3. Do you own stocks or shares in companies that may gain or lose financially from the publication of reviews by your review group in the CDSR?
No

4. Do you hold any patents for products that that may lead you to gain or lose financially from the publication of reviews by your review group in the CDSR?
No

5. Do you have any other competing interests (financial or non-financial)?
Yes - Chief Investigator of NIHR HTA funded trial comparing standard and new anti epileptic drugs: SANAD 2